Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.